|Day Low/High||51.14 / 51.98|
|52 Wk Low/High||48.01 / 66.55|
It took 12 months for Teva to gain FTC approval to buy Allergan's U.S. generics business. Future mergers could face the same long scrutiny.
The pharmaceutical company announced that it will increase its patient assistance program in hopes of quelling a growing backlash over its drug pricing.
Despite Teva Pharmaceuticals (TEVA) losing two patents for its Copaxone drug, Leerink said generics won't challenge the company until 2018.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today confirmed the Patent Trial and Appeal Board (PTAB) decisions from an Inter Partes Review (IPR) to invalidate all claims of the '250 and '413 patents for 40 mg...
The pharma company has been increasing the price of the epinephrine injector since 2007, so why are people finally taking notice?
Shares of the world's second largest generic pharma company fell nearly 5% after U.S. politicians target company for price gouging.
Teva was stock was trading sharply lower this afternoon after aspects of its patent for multiple sclerosis drug Copaxone were determined invalid.
Senators Grassley, Blumenthal and Klobuchar demand Mylan reduce the price of its dominant treatment for life-threatening allergies.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the European Commission has granted marketing authorization for CINQAERO ® (reslizumab) in the 28 countries of the European Union (EU) in...
The Dublin-based drugmaker has some 65-plus mid-to-late stage assets in its pipeline.
The deal for ForSight VISION5 aligns with the bolt-on M&A strategy described by CEO Brent Saunders earlier this week.
The Pittsburgh-based pharmaceutical company has been steadily jacking up the price of the auto injectors since 2010 to bolster revenues.
AAP portfolio managers Cramer and Mohr defend the drug company after it tops analysts' bottom-line expectations while missing top-line estimates.
Here's a technical look at how to trade some of the most active stocks on the market right now.
Allergan shares are down but management will take the opportunity to buy back its stock, Cramer says.
Here are Friday's top research calls, including downgrades for FireEye and Teva Pharmaceuticals, and upgrades for Kraft Heinz and U.S. Steel.
Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) today announced the launch of the generic equivalent to Gleevec ®1(imatinib mesylate) tablets,100 mg and 400 mg, in the United States for multiple indications...
Rarely do investors get to buy these types of quality businesses at such discounted prices.
Allergan stock is down 19% year to date, but probably not for long. Over the next year, Allergan could trade much higher.
Teva Pharmaceuticals (TEVA) reported better-than-expected earnings and revenue before today's market open.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today reported results for the quarter ended June 30, 2016.
The stock is breaking out of consolidation patterns on multiple timeframes.
Deal rumors are deflating, but a takeover bid could reward holdouts.
Teva Pharmaceuticals (TEVA) is slated to report second-quarter earnings and revenue before tomorrow's market open.
Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced that it has entered into a definitive agreement to purchase Allergan's Anda Inc.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Allergan plc (NYSE: AGN) today announced that Teva has completed its acquisition of Allergan's generics business ("Actavis Generics").
These five technical setups are showing solid upside potential right now. Here's how to trade them from here.